These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32633541)

  • 1. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
    Taylor JH; Appel S; Eli M; Alexander-Bloch A; Maayan L; Gur RE; Bloch MH
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):46-52. PubMed ID: 32633541
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
    Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
    Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
    Findling RL; Johnson JL; McClellan J; Frazier JA; Vitiello B; Hamer RM; Lieberman JA; Ritz L; McNamara NK; Lingler J; Hlastala S; Pierson L; Puglia M; Maloney AE; Kaufman EM; Noyes N; Sikich L
    J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):583-94; quiz 632. PubMed ID: 20494268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
    Frazier JA; Giuliano AJ; Johnson JL; Yakutis L; Youngstrom EA; Breiger D; Sikich L; Findling RL; McClellan J; Hamer RM; Vitiello B; Lieberman JA; Hooper SR
    J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):496-505. PubMed ID: 22525956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.
    McCLELLAN J; Sikich L; Findling RL; Frazier JA; Vitiello B; Hlastala SA; Williams E; Ambler D; Hunt-Harrison T; Maloney AE; Ritz L; Anderson R; Hamer RM; Lieberman JA
    J Am Acad Child Adolesc Psychiatry; 2007 Aug; 46(8):969-978. PubMed ID: 17667476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.
    Taylor JH; Jakubovski E; Gabriel D; Bloch MH
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):474-484. PubMed ID: 29920116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
    Gabriel D; Jakubovski E; Taylor JH; Artukoglu BB; Bloch MH
    Psychiatry Res; 2017 Sep; 255():248-255. PubMed ID: 28595147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
    Bachman P; Jalbrzikowski M; Bearden CE
    J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):464-6. PubMed ID: 22525952
    [No Abstract]   [Full Text] [Related]  

  • 10. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
    Croarkin PE; Daskalakis ZJ
    J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):949-51. PubMed ID: 22917209
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
    Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
    BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.
    Stentebjerg-Olesen M; Jeppesen P; Pagsberg AK; Fink-Jensen A; Kapoor S; Chekuri R; Carbon M; Al-Jadiri A; Kishimoto T; Kane JM; Correll CU
    J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):665-75. PubMed ID: 24266529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM
    Neuropsychopharmacology; 2010 Jan; 35(2):581-90. PubMed ID: 19890258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
    Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
    Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.